Previous 10 | Next 10 |
Strategic Prioritization to Deliver Savings of $40M Through End of 2023 Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a pioneer in immuno-oncology, today announced a strategic initiative to prioritize and focus resources to accelerate the development, registration, and commercial...
2023-08-23 05:36:55 ET Summary MiNK Therapeutics is developing "off the shelf" allogeneic cell therapies for cancer using iNKT cells. Their first iNKT cell therapy, agenT-797, showed a pro-inflammatory cytokine response and some efficacy in patients with solid tumors. The comp...
2023-08-20 12:00:00 ET Ahead of the world's first immunization drive against respiratory syncytial virus (RSV), a new report from the London-based health analytics firm Airfinity suggests RSV vaccine sales for older adults could exceed $10B by 2030 in G7 countries. For years, RSV was an...
2023-08-18 10:19:27 ET Gainers: Aditxt ( ADTX ) +50% . AlloVir ( ALVR ) +18% . Agenus ( AGEN ) +7% . Veru ( VERU ) +7% . Akari Therapeutics ( AKTX ) +6% . Losers: Evelo Biosciences ( EVLO ) -37% . Diffusi...
2023-08-09 11:43:49 ET Biotechnology company Agenus Inc's ( NASDAQ: AGEN ) unit SaponiQx Wednesday said it successfully manufactured STIMULON cultured plant cell (cpc) QS-21, showing biochemical comparability to traditional bark extract-derived adjuvants. This method eliminate...
Successful production of STIMULON™ cpcQS-21, a cultured plant cell adjuvant with confirmed biochemical comparability to traditional bark extract-derived adjuvant Submission of Master File (MF) for STIMULON cpcQS-21 to the U.S. FDA for reference by partners as part of regulatory submiss...
2023-08-08 07:53:00 ET Agenus press release ( NASDAQ: AGEN ): Q2 GAAP EPS of -$0.20 in-line. Revenue of $25.3M (+20.9% Y/Y) beats by $1.17M . We ended our second quarter 2023 with a cash, cash equivalent and short-term investment balance of $157.6 million, compared...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results for the second quarter 2023. Key accomplishments and highlights include: Botensilimab Update: Botensilimab/balstilimab combination...
2023-08-07 13:30:15 ET Agenus ( NASDAQ: AGEN ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, before market open. The consensus EPS Estimate is -$0.20 and the consensus Revenue Estimate is $24.13M (+15.3% Y/Y). Over the last 3 months, EPS estimate...
Immuno-oncology leader, Agenus Inc. (“Agenus”) (Nasdaq: AGEN), today announced a data update from the phase 1 expansion cohort of botensilimab (multifunctional CTLA-4 antibody) in combination with balstilimab (PD-1 antibody) for patients with advanced, refractory sarcomas has been s...
News, Short Squeeze, Breakout and More Instantly...
Extended BOT/BAL Therapy Yields Pronounced Improvements in Tumor Reductions Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-sponsored trial (IST) of botensilim...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using botensilimab (BOT), a huma...
2024-06-27 01:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...